Sindhu Chitikela

Medical Oncology Resident

[Sindhu Chitikela @drcsindhu]

@annie_baa @aparna96 @ConquerCancerFd @aiims_newdelhi @atul1_p Congratulations Mam!

[K Pavithran @drkpavithran]

Low-dose, olanzapine (2.5mg/day) significantly improves appetite and weight gain in newly diagnosed patients with advanced lung and upper gastrointestinal cancers on chemotherapy
https://t.co/zTqJbpy9Su

[Jordi Remon @JordiRemon]

Final OVERALL SURVIVAL 🍎 APPLE trial in EGFRm NSCLC: comparable OS: osimertinib vs Gefitinib -> Osi (82% received osi at PD). Osi upfront ⬇️46% risk of 🧠 PD (really relevant for pts!!).Is there a room for de-escalating?price of drugs should ⬇️ if no OS impact?@myESMO#ELCC2023

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

😳😳😳 🇯🇵 ORR 90.9%, mPFS 31.0 months, and mOS not reached.

Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR-Mutated Advanced Non-Squamous Non-Small Cell Lung Cancer: The OPAL Study. #LCSM https://t.co/Xo2RCIdZfw

[Aakash Desai @ADesaiMD]

As @HemOncFellows , #bcsm management has become increasingly complex! Below is a #study guide for #MedOnc #MedEd fellows I have been working on :
What do you think? 🧐 @IlanaSchlam @PTarantinoMD @OncBrothers @rleonferre
🛑 #WorkinProgress #NotMedicalAdvice
🙏 #InputsWelcome

[Gaurav Prakash M.D. @DrGPrakash]

A great amalgamation of 120+ Alumni at the Mecca of teaching in #MedicalOncology, #AIIMS, #NewDelhi. 📖📚
May the flame of knowlwdge ignited here shine far and wide. 🕯🕯🔥 @aiims_newdelhi @atul1_p @batraatulmd @Prabhatmalikmd @RanjitKSMD @aparna96 @dr_rajapramanik

[Aparna Sharma @aparna96]

Wonderful two days spent with all generations of luminaries and doyens of oncology in India at the @aiims_newdelhi Medical Oncology Annual RESMO and Alumni meet! Reminiscing old times ,brainstorming on academics and getting inspired at IRCH and NCI. @atul1_p @batraatulmd

[Sindhu Chitikela @drcsindhu]

@drneha1pathak Congratulations!

[Pauline Funchain @FunchainMD]

Everything you need to know about infliximab in 3 slides - great talk on therapies used in steroid refractory irAEs by @SowmyaTakk at #irAE23

[Hagop Kantarjian,MD @DrHKantarjian]

#CML with no MMR after 2 years of TKI is not adverse. Favorable outcomes are seen even with BCR::ABL 1-10%
@AbidikianMD @MDAndersonNews #Leukemia
https://t.co/KI5q4fmkT5 via @AjHematology
#leusm

[Annie K Baa @annie_baa]

Our paper on mutation analysis in GIST, and it’s impact on management#sarcoma#AIIMSdelhi#
Glad to have the study published with #ecancer #simple#hasslefree#

[Dr (Prof). Vijay Patil @DrVijayPatil11]

3-gene immune score classified HPV positive oropharyngeal patients into three immune classes (immune rich, mixed, or immune desert). Immune rich does the best. We can now probably identify patients who can do well with even 30 Gy RT @HHKhar @DrHaddadRobert https://t.co/ZYXGIUeXXq